Last reviewed · How we verify

NCT05383651

Post Market, Prospective Multicenter Observational Study of the Safety and Performance of Bellavista Ventilator

Completed Last updated 5 September 2024
What this trial tests

trial testing bellavista 1000 in Ventilation Therapy; Complications in 350 participants. Completed in 30 June 2024.

Timeline
1 February 2023
Primary endpoint
31 May 2024
30 June 2024

Quick facts

Lead sponsorVyaire Medical
StatusCompleted
Study typeOBSERVATIONAL
Enrollment350
Start date1 February 2023
Primary completion31 May 2024
Estimated completion30 June 2024
Sites2 locations across Canada, Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

Vyaire Medical

Who can join

6 Months and older, any sex, with Ventilation Therapy; Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective post market clinical follow up (PMCF) study will evaluate the safety and performance of bellavista ventilator and the iFlow sensors in daily clinical routine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Ventilation Therapy; Complications

Currently open trials in the same condition.

Other Vyaire Medical trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05383651.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing